Monitor patients closely for diarrhea, a common side effect. Severe, persistent diarrhea may indicate *Clostridium difficile* infection – seek immediate medical attention if this occurs. Consider alternative antibiotics if the patient has a history of colitis.
Clindamycin can cause pseudomembranous colitis, a potentially life-threatening condition. Early recognition and treatment with appropriate antibiotics (e. g., vancomycin or fidaxomicin) are crucial.
Blood tests (complete blood count) are recommended to monitor for neutropenia, especially in patients receiving high doses or prolonged treatment.
Liver function tests should be performed, particularly in patients with pre-existing liver disease. Hepatotoxicity is a potential, albeit rare, adverse event.
Use cautiously in patients with impaired renal or hepatic function; dosage adjustment may be necessary. Always refer to prescribing information for detailed guidance.
Concomitant use with neuromuscular blocking agents (e. g., succinylcholine, tubocurarine) can enhance their effects, potentially leading to respiratory depression. Close monitoring is advised.
Clindamycin may interact with oral anticoagulants (e. g., warfarin), increasing the risk of bleeding. Regular INR monitoring is needed during concurrent therapy.
Avoid concurrent administration with erythromycin as this may result in decreased clindamycin efficacy.
Inform patients about potential side effects, including nausea, vomiting, abdominal pain, and rash. Encourage immediate reporting of any unusual symptoms.
